Takeda Pharmaceutical (TAK) Total Non-Current Liabilities: 2018-2025

  • Takeda Pharmaceutical's Total Non-Current Liabilities fell 15.46% to $31.5 billion in Q1 2025 from the same period last year, while for Mar 2025 it was $31.5 billion, marking a year-over-year decrease of 15.46%. This contributed to the annual value of $31.5 billion for FY2025, which is 17.60% down from last year.
  • Latest data reveals that Takeda Pharmaceutical reported Total Non-Current Liabilities of $31.5 billion as of Q1 2025, which was down 15.46% from $37.3 billion recorded in Q1 2024.
  • Over the past 5 years, Takeda Pharmaceutical's Total Non-Current Liabilities peaked at $56.3 billion during Q1 2021, and registered a low of $31.5 billion during Q1 2025.
  • In the last 3 years, Takeda Pharmaceutical's Total Non-Current Liabilities had a median value of $37.3 billion in 2024 and averaged $35.8 billion.
  • As far as peak fluctuations go, Takeda Pharmaceutical's Total Non-Current Liabilities climbed by 3.63% in 2021, and later decreased by 18.29% in 2022.
  • Over the past 5 years, Takeda Pharmaceutical's Total Non-Current Liabilities (Quarterly) stood at $56.3 billion in 2021, then fell by 18.29% to $46.0 billion in 2022, then fell by 15.88% to $38.7 billion in 2023, then declined by 3.76% to $37.3 billion in 2024, then decreased by 15.46% to $31.5 billion in 2025.
  • Its Total Non-Current Liabilities stands at $31.5 billion for Q1 2025, versus $37.3 billion for Q1 2024 and $38.7 billion for Q1 2023.